Research shows there is a 92 percent reduction in anti-factor Xa activity with a dose of Andexxa, and 82 percent of patients given the drug returned to “excellent” or “good” hemostasis. The drug is released as a bolus at a rate of 30 mg/minute, with continuous infusion sustained for up to 120 minutes. Medical care providers administer the drug as a lyophilized powder dissolved in solution for intravenous injection. Andexxa works by targeting and binding to Factor Xa molecules, enzymes that aid in blood clotting. Unlike Warfarin, there was no known antidote for Xarelto or Eliquis, should an adverse bleeding event occur.Īndexxa is a drug developed by Portola Pharmaceuticals for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Patients liked that the dosage of these newer drugs did not depend on routine blood work, diet, exercise, or alcohol consumption. Xarelto and Eliquis were introduced as next-generation blood thinners to prevent stroke and treat atrial fibrillation complications. Vitamin K or Fresh Frozen Plasma – for treating Coumadin (warfarin) patients.Praxbind (idarucizumab) – for treating Pradaxa (dabigatran) patients.It’s uncertain how many deaths Andexxa could have prevented, but many patients are now wondering why their hospitals don’t carry the life-saving drug and what can be done to make them accountable for this negligence.Īs an antidote, Andexxa (andexanet alfa) works as a factor xa inhibitor for:Īndexxa has not been approved for Savaysa (edoxaban) or Bevyxxa (betrixaban) – for which there are no specific FDA-approved antidotes.Īlternative blood thinner reversal agents are available on the market: In 2016, there were approximately 117,000 hospital admissions related to Factor Xa-inhibitor-related bleeding and approximately 2,000 bleeding-related deaths every month in the United States.
Despite the fact that this blood thinner reversal agent is the only known “antidote” to bleeding caused by Xarelto and Eliquis, and despite the fact that it has been shown to be safe and effective, many hospitals are refusing to carry Andexxa because “the price is too high.” The result is that people are still dying of uncontrolled bleeding - unnecessarily.
0 kommentar(er)
